- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02130063
IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose (Provide)
A Phase III, Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose in Subjects With Iron Deficiency Anaemia and Who Are Intolerant or Unresponsive to Oral Iron Therapy or Who Need Iron Rapidly (PROVIDE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
IDA is highly prevalent in subjects with gastrointestinal diseases and cancer, menstruating or pregnant women, and subjects who have undergone bariatric procedure. IDA can have a substantial medical and quality of life (QoL) burden on the subjects and the treatment of these subjects includes controlling the bleeding and replenishing lost iron. Oral iron administration is often used in the clinical practice at many clinics; however, oral iron may not be tolerated by all subjects. Hence, there is a need for an alternative iron treatment in subjects, who do not tolerate oral iron.
This study is planned to compare the efficacy and safety of iron isomaltoside 1000 with another parenteral iron preparation (iron sucrose) in subjects with IDA and who are intolerant or unresponsive to oral iron therapy or who need iron rapidly.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Delaware
-
Wilmington, Delaware, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men or women > 18 years having IDA caused by different aetiologies such as abnormal uterine bleeding, gastrointestinal diseases, cancer, bariatric procedures (gastric bypass operations), and other conditions leading to significant blood loss and with a documented history of intolerance or unresponsiveness to oral iron therapy for at least one month prior to study enrollment or where there at investigators judgment is a clinical need to deliver iron rapidly
- Hb < 11 g/dL
- TSAT < 20 %
- S-ferritin < 100 ng/mL
- Willingness to participate and signing the informed consent form
Exclusion Criteria:
- Anaemia predominantly caused by factors other than IDA (e.g. anaemia with untreated vitamin B12 or folate deficiency, haemolytic anaemia)
- Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis)
- Decompensated liver cirrhosis or active hepatitis (ALAT > 3 times upper limit of normal)
- Active acute or chronic infections (assessed by clinical judgement supplied with white blood cells (WBC) and C-reactive protein (CRP))
- Body weight < 50 kg
- Rheumatoid arthritis with symptoms or signs of active inflammation
- Pregnant or nursing women. In order to avoid pregnancy, women have to be surgically sterile or use adequate contraception (e.g. intrauterine devices, hormonal contraceptives, or double barrier method) during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product
- History of multiple allergies
- Known hypersensitivity to parenteral iron or any excipients in the investigational drug products
- Erythropoietin treatment within 8 weeks prior to the screening visit
- Other iron treatment or blood transfusion within 4 weeks prior to the screening visit
- Planned elective surgery during the study
- Participation in any other clinical study within 3 months prior to the screening
- Any other medical condition that, in the opinion of Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study, e.g. uncontrolled hypertension, unstable ischaemic heart disease, or uncontrolled diabetes mellitus
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: iron isomaltoside 1000 (Monofer®)
|
|
Active Comparator: iron sucrose (Venofer®)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With an Haemoglobin (Hb) Increase of ≥ 2 g/dL From Baseline at Any Time From Week 1 to Week 5
Time Frame: From baseline to week 5
|
The primary efficacy endpoint of the trial was the count of subjects with an Hb increase of ≥ 2 g/dL from baseline at any time from week 1 to week 5. 'Any time' implied that if the endpoint was met at a time-point prior to or at week 5, the effect (increase of ≥ 2 g/dL) did not have to be maintained throughout the trial in order for a subject to be a responder. Number of responders (i.e. a subject with increase in Hb ≥ 2 g/dL from baseline at any time from week 1 to week 5) and percentages according to number of subjects in the analysis set were summarised. |
From baseline to week 5
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Hb Concentration
Time Frame: From baseline to week 2, 4 and 5
|
From baseline to week 2, 4 and 5
|
Change in Serum (s)-Ferritin Concentration
Time Frame: From baseline to week 1, 2, 4, and 5
|
From baseline to week 1, 2, 4, and 5
|
Change in Transferrin Saturation (TSAT)
Time Frame: From baseline to week 1, 2, 4, and 5
|
From baseline to week 1, 2, 4, and 5
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P-Monofer-IDA-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Iron Deficiency Anaemia
-
Shield TherapeuticsMedpace, Inc.CompletedIron Deficiency, Anaemia in Children | Iron-DeficiencyUnited Kingdom
-
Carleton UniversityHopital Montfort; University of Ottawa; Lucky Iron Fish EnterpriseRecruitingIron Deficiency | Iron Deficiency AnaemiaCanada
-
American Regent, Inc.WithdrawnIron Deficiency, AnaemiaUnited States
-
Medical Research CouncilCompletedIron Deficiency AnaemiaUnited Kingdom
-
Mahidol UniversityCompletedEffect of a Dietary Iron Program on Iron Status and IQ in Children in Phatthalung Province, ThailandIron Deficiency, Anaemia in ChildrenThailand
-
Pharmacosmos A/SRecruitingIron Deficiency, Anaemia in ChildrenUnited States
-
Nadirah Rasyid RidhaHasanuddin UniversityCompletedIron Deficiency, Anaemia in ChildrenIndonesia
-
London School of Hygiene and Tropical MedicineKing's College London; Wellcome Trust; University of Cambridge; National Nutrition... and other collaboratorsCompletedIron Deficiency, Anaemia in ChildrenGambia
-
London School of Hygiene and Tropical MedicineCompletedIron-deficiency | Anaemia in Early InfancyGambia
-
Sichuan Huiyu Pharmaceutical Co., LtdThe First Hospital of Jilin University; Suzhou Guochen Biotek Co., Ltd.; Boji... and other collaboratorsCompletedBioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency AnaemiaIron Deficiency | AnaemiaChina
Clinical Trials on iron isomaltoside 1000 (Monofer®)
-
Pharmacosmos A/SMax NeemanCompleted
-
Pharmacosmos UK LtdBioStataCompletedIron Deficiency AnaemiaUnited Kingdom
-
Pharmacosmos A/SBioStataCompletedIron Deficiency AnemiaDenmark
-
Pharmacosmos A/SCompleted
-
Pharmacosmos A/SCompletedInflammatory Bowel DiseaseDenmark
-
Yonsei UniversityCompletedComplex Valvular Heart SurgeryKorea, Republic of
-
Pharmacosmos A/SCompletedPatients With Chemotherapy Induced Anemia (CIA)United States
-
Pharmacosmos A/SCompletedAnemia | Iron Metabolism Disorders | Deficiency Diseases | Anemia, Iron Deficiency | Hematologic DiseaseJapan
-
Nottingham University Hospitals NHS TrustPharmacosmos A/SUnknownAnemia | Gastric Cancer | Esophageal CancerUnited Kingdom
-
Pharmacosmos A/SCompletedIron Deficiency Anemia | Iron Deficiency AnaemiaUnited States